Your browser is no longer supported. Please, upgrade your browser.
Settings
CTSO Cytosorbents Corporation daily Stock Chart
CTSO [NASD]
Cytosorbents Corporation
Index- P/E- EPS (ttm)-0.65 Insider Own4.50% Shs Outstand31.59M Perf Week3.31%
Market Cap147.84M Forward P/E- EPS next Y-0.43 Insider Trans2.05% Shs Float28.87M Perf Month19.69%
Income-20.70M PEG- EPS next Q-0.17 Inst Own26.80% Short Float8.63% Perf Quarter-2.30%
Sales23.60M P/S6.26 EPS this Y-75.90% Inst Trans-0.07% Short Ratio13.51 Perf Half Y-35.54%
Book/sh0.21 P/B22.29 EPS next Y31.70% ROA-67.70% Target Price11.90 Perf Year-32.86%
Cash/sh0.51 P/C9.24 EPS next 5Y- ROE-165.00% 52W Range3.49 - 8.61 Perf YTD21.56%
Dividend- P/FCF- EPS past 5Y5.60% ROI-55.60% 52W High-45.64% Beta1.73
Dividend %- Quick Ratio2.20 Sales past 5Y56.20% Gross Margin68.80% 52W Low34.10% ATR0.19
Employees153 Current Ratio2.40 Sales Q/Q7.00% Oper. Margin-81.10% RSI (14)67.56 Volatility4.07% 4.94%
OptionableYes Debt/Eq2.24 EPS Q/Q-121.60% Profit Margin-87.80% Rel Volume1.09 Prev Close4.61
ShortableYes LT Debt/Eq1.78 EarningsFeb 04 AMC Payout- Avg Volume184.33K Price4.68
Recom2.00 SMA2014.43% SMA5014.53% SMA200-15.29% Volume201,824 Change1.52%
Aug-08-17Reiterated Maxim Group Buy $10 → $12
Oct-26-16Initiated Aegis Capital Buy
May-24-16Initiated Maxim Group Buy $8
Oct-29-15Upgrade WBB Securities Speculative Buy → Buy $13 → $13
May-12-15Reiterated MLV & Co Buy $28 → $21
Apr-01-15Reiterated MLV & Co Buy $28 → $30
Mar-05-15Initiated MLV & Co Buy $30
Feb-25-15Initiated WBB Securities Speculative Buy $13
Jan-27-15Reiterated H.C. Wainwright Buy $1 → $12
Jan-22-20 06:30AM  CytoSorb Treatment Improves Rat Survival Following Lethal Intravenous Dose of Fungal Aflatoxin PR Newswire
Jan-14-20 09:30AM  CytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter PR Newswire +5.57%
Jan-10-20 04:11PM  2 Healthcare Stocks Set to Rally into the New Year TipRanks
Jan-07-20 10:13AM  CytoSorbents to Present at Biotech Showcase 2020 PR Newswire
Dec-20-19 05:02PM  Is Cytosorbents Corporation (CTSO) A Good Stock To Buy? Insider Monkey
Dec-11-19 05:23AM  Trade Alert: The CEO, President & Director Of Cytosorbents Corporation (NASDAQ:CTSO), Phillip Chan, Has Just Spent US$59k Buying Shares Simply Wall St.
Dec-02-19 07:45AM  CytoSorbents to Present at the Piper Jaffray 31st Annual Healthcare Conference PR Newswire
Nov-25-19 07:00AM  CytoSorbents Changes Contract Research Organizations and Temporarily Pauses Enrollment in REFRESH 2-AKI Study PR Newswire -7.36%
Nov-19-19 07:00AM  CytoSorbents to Present at the Three Part Advisors 2019 Southwest IDEAS Investor Conference PR Newswire
Nov-06-19 05:15PM  Dr. Eric Mortensen to Leave CytoSorbents At Year End PR Newswire -6.90%
Nov-05-19 04:15PM  CytoSorbents Reports Third Quarter 2019 Financial Results PR Newswire
05:52AM  Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt? Simply Wall St.
Nov-04-19 07:05AM  CytoSorbents Announces Additions to its International Clinical Team PR Newswire
Nov-01-19 07:15AM  CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom PR Newswire
Oct-30-19 07:30AM  CytoSorbents to Report Q3 2019 Operating and Financial Results PR Newswire
Oct-22-19 08:12AM  CytoSorbents Awarded Approximately $3.0 Million by the U.S. Air Force to Advance Development of the K+ontrol System to Treat Severe Hyperkalemia PR Newswire
Oct-15-19 08:00AM  MicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019 ACCESSWIRE
Oct-11-19 06:59AM  Is Cytosorbents Corporation's (NASDAQ:CTSO) CEO Salary Justified? Simply Wall St. +9.88%
Oct-10-19 07:00AM  CytoSorbents to Present at The MicroCap Rodeo Investor Conference PR Newswire
Oct-04-19 07:08AM  CytoSorb® Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac Surgery PR Newswire
Oct-02-19 08:24AM  CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery PR Newswire
Sep-25-19 06:58AM  CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock PR Newswire
Sep-21-19 08:44AM  Analysts Expect Breakeven For Cytosorbents Corporation (NASDAQ:CTSO) Simply Wall St.
Sep-19-19 10:15AM  MicroCap Rodeo Investor Conference - October 15 and 16, 2019, Austin Texas ACCESSWIRE
Sep-16-19 07:00AM  First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence PR Newswire
Sep-13-19 07:08AM  World Sepsis Day 2019: CytoSorbents Highlights Its Support of Multiple Organizations In the Fight Against Sepsis PR Newswire
Sep-09-19 07:00AM  CytoSorbents to Present at the H.C. Wainwright 21st Annual Global Investment Conference PR Newswire +6.42%
Aug-28-19 09:51AM  CytoSorbents Highlights Recent Published Studies on CytoSorb PR Newswire
Aug-26-19 07:18AM  With A -17% Earnings Drop, Is Cytosorbents Corporation's (NASDAQ:CTSO) A Concern? Simply Wall St.
Aug-22-19 09:45AM  CTSO: Q2 19: Product Sales Rebound to Record High Despite Distributor Hangover. Value-Inflection Opportunities Abound Zacks Small Cap Research
Aug-15-19 01:54PM  CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022 PR Newswire -5.92%
Aug-13-19 07:08AM  CytoSorbents Expands CytoSorb Distribution in Latin America to Brazil, Colombia, and Costa Rica PR Newswire
Aug-07-19 09:24PM  Cytosorbents (CTSO) Q2 2019 Earnings Call Transcript Motley Fool -14.07%
Aug-06-19 04:15PM  CytoSorbents Reports Record Second Quarter 2019 Financial Results PR Newswire
Aug-05-19 05:00PM  CytoSorbents Announces Amendment to Loan Agreement with Bridge Bank, Receives an Additional $5 Million Cash from New Term Loan PR Newswire
Aug-01-19 11:34AM  The Cytosorbents (NASDAQ:CTSO) Share Price Is Down 46% So Some Shareholders Are Getting Worried Simply Wall St.
Jul-30-19 07:00AM  CytoSorbents to Report Q2 2019 Operating and Financial Results PR Newswire
Jun-26-19 03:25PM  Do Insiders Own Shares In Cytosorbents Corporation (NASDAQ:CTSO)? Simply Wall St.
Jun-18-19 06:30AM  CytoSorbents to Present at the Raymond James Life Sciences and MedTech Conference PR Newswire
Jun-11-19 07:00AM  CytoSorbents to Present at the Three Part Advisors 2019 East Coast IDEAS Investor Conference PR Newswire
Jun-07-19 07:48AM  Does Market Volatility Impact Cytosorbents Corporation's (NASDAQ:CTSO) Share Price? Simply Wall St.
Jun-03-19 07:00AM  CytoSorbents to Present at the Jefferies 2019 Global Healthcare Conference PR Newswire
May-20-19 07:00AM  CytoSorbents to Participate at the B. Riley FBR 20th Annual Institutional Investor Conference PR Newswire
May-09-19 03:30PM  CTSO: Distributor Sales Take a Breather But Expected to Rebound. Direct Sales Remain Robust Zacks Small Cap Research -6.36%
May-07-19 07:33PM  CytoSorbents: 1Q Earnings Snapshot Associated Press
04:15PM  CytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance PR Newswire
May-01-19 07:00AM  CytoSorbents to Report Q1 2019 Operating and Financial Results PR Newswire
Apr-24-19 07:08AM  CytoSorbents Highlights the 6th International CytoSorb Users' Meeting and Recent Activities at the 2019 ISICEM and EuroELSO Conferences PR Newswire
Apr-08-19 05:30AM  CytoSorbents to Present at the H.C. Wainwright Global Life Sciences Conference 2019 London PR Newswire
Mar-25-19 07:10AM  Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor PR Newswire
Mar-11-19 04:20PM  CTSO: Q4 2018: Product Sales +27%, Expenses Jump In Part Due to Investments Aimed at Further Accelerating Growth Zacks Small Cap Research
Mar-07-19 10:00PM  Cytosorbents Corp (CTSO) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:15PM  CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018 PR Newswire
Mar-06-19 07:00AM  CytoSorbents to Present at the Cowen 39th Annual Health Care Conference PR Newswire
Mar-05-19 07:10AM  CytoSorbents Expands Direct Sales to Poland, the Nordics, and the Netherlands PR Newswire
Feb-28-19 07:00AM  CytoSorbents to Report Fiscal 2018 Operating and Financial Results PR Newswire
Feb-25-19 07:08AM  CytoSorbents to Participate at the 8th Annual SVB Leerink Global Healthcare Conference PR Newswire
Feb-05-19 07:00AM  CytoSorbents to Present at the 21st Annual BIO CEO & Investor Conference PR Newswire
Feb-04-19 03:00PM  CTSO: DSMB Recommends Continuance of REMOVE Study: Has several important implications Zacks Small Cap Research +5.24%
06:58AM  CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial PR Newswire
Feb-01-19 11:30AM  LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index ACCESSWIRE
Jan-23-19 07:45AM  Detailed Research: Economic Perspectives on Shell Midstream Partners, Interface, National Western Life Group, TPG Specialty Lending, Francesca's, and Cytosorbents What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jan-22-19 07:08AM  CytoSorbents Announces Expansion of CytoSorb® Partnership with Fresenius Medical Care PR Newswire -5.71%
Jan-18-19 02:22PM  Is Cytosorbents Corporations (NASDAQ:CTSO) CEO Pay Fair? Simply Wall St.
Jan-07-19 03:45PM  CTSO: Q4 / FY 2018: Record Product Sales in Q4, Jumps 51% in 2018 Zacks Small Cap Research +6.34%
09:20AM  CytoSorbents Issues Stockholder Letter with Preliminary 2018 Financial Results PR Newswire
Jan-04-19 07:00AM  CytoSorbents To Highlight Progress at Biotech Showcase 2019 PR Newswire +6.06%
Dec-21-18 08:45AM  CytoSorbents To Receive $619,546 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program PR Newswire -7.36%
Dec-10-18 02:13PM  Is Cytosorbents Corporations (NASDAQ:CTSO) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Nov-26-18 07:00AM  CytoSorbents to Present at the 30th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-19-18 07:08AM  CytoSorbents Recognized Again as One of the Fastest Growing Companies in North America on Deloitte's 2018 Technology Fast 500 PR Newswire
Nov-12-18 07:08AM  CytoSorbents to Present at the Stifel, Jefferies, and Canaccord Investor Conferences This Week PR Newswire
Nov-09-18 09:45AM  CTSO: Q3: Another Solid Quarter. Financials In-Line, REFRESH II Enrollment Accelerating Zacks Small Cap Research -8.03%
08:00AM  Market Trends Toward New Normal in Paramount Group, Envestnet, Assurant, HubSpot, Epizyme, and Cytosorbents Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-06-18 06:25PM  CytoSorbents: 3Q Earnings Snapshot Associated Press
04:15PM  CytoSorbents Reports Third Quarter 2018 Financial Results PR Newswire
Nov-01-18 02:22PM  Cytosorbents Corporation (NASDAQ:CTSO) Is Trading At A 28.36% Discount Simply Wall St.
Oct-31-18 07:00AM  CytoSorbents to Report Q3 2018 Operating and Financial Results PR Newswire
Oct-18-18 09:30AM  CytoSorbents to Showcase CytoSorb® at Two Key European Medical Conferences PR Newswire
Oct-15-18 07:45AM  Detailed Research: Economic Perspectives on LifePoint Health, Carter's, Lincoln Electric, Cytosorbents, ServiceNow, and Chimera Investment What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-03-18 07:10AM  CytoSorbents to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-20-18 07:55AM  CytoSorb® Assigned Dedicated Procedure Code in Switzerland PR Newswire
Sep-14-18 11:33AM  Do You Know Who Else Invests In Cytosorbents Corporation (NASDAQ:CTSO)? Simply Wall St.
Sep-13-18 07:08AM  World Sepsis Day 2018: CytoSorbents Sponsors the Sepsis Heroes Gala and the Roger Bone Award for Excellence in Sepsis Research PR Newswire
Sep-05-18 09:45AM  CTSO: FDA Approves REFRESH-2 Protocol Amendment Zacks Small Cap Research
Sep-04-18 07:05AM  CytoSorbents REFRESH 2-AKI Protocol Amendment Approved by FDA PR Newswire
Aug-29-18 06:03PM  Cytosorbents Stock Could Score Big With Its Blood-Filtering Technology InvestorPlace +6.99%
Aug-21-18 05:49PM  Edited Transcript of CTSO earnings conference call or presentation 2-Aug-18 8:45pm GMT Thomson Reuters StreetEvents
09:06AM  CytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend Blood Transfusion Filter PR Newswire
Aug-08-18 12:30PM  CTSO: Q2 Product Sales Beat Big. New Catalysts Come Online. Moving PT to $15/share Zacks Small Cap Research
08:10AM  Report: Developing Opportunities within Cytosorbents, Nasdaq, Mastercard, Maxim Integrated Products, Bristol-Myers Squibb, and Equity Lifestyle Properties Future Expectations, Projections Moving into 2018 GlobeNewswire
Aug-03-18 05:09AM  CytoSorbents: 2Q Earnings Snapshot Associated Press -9.88%
Aug-02-18 04:15PM  CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018 PR Newswire
02:45PM  CytoSorbents Corporation to Host Earnings Call ACCESSWIRE
Jul-31-18 07:08AM  CytoSorbents Expands Distribution of CytoSorb® to a Total of 53 Countries Worldwide PR Newswire
Jul-26-18 07:00AM  CytoSorbents to Report Q2 2018 Operating and Financial Results PR Newswire
Jul-09-18 08:00AM  Aferetica and CytoSorbents Debut the PerLife System for Organ Preservation and Rehabilitation at the 27th International Congress of the Transplantation Society PR Newswire +6.52%
Jun-26-18 07:08AM  CytoSorbents Added to the Russell 2000 and Russell 3000 Indexes PR Newswire
Jun-12-18 07:08AM  CytoSorbents Officially Opens New U.S. CytoSorb Manufacturing Facility PR Newswire
Jun-04-18 07:30AM  CytoSorbents to Present at the Jefferies 2018 Global Healthcare Conference PR Newswire
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, the company develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; K+ontrol, a development stage blood purification technology; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BLOCH KATHLEEN P.Chief Financial OfficerDec 10Buy3.683,00011,030291,895Dec 10 01:30 PM
Chan Phillip P.President and CEODec 06Buy3.6016,50059,400657,688Dec 06 11:45 AM
BLOCH KATHLEEN P.Chief Financial OfficerNov 26Buy4.271,0004,27021,000Nov 26 06:30 PM
Capponi VincentChief Operating OfficerAug 16Option Exercise4.334,60019,895372,501Aug 16 04:23 PM
BLOCH KATHLEEN P.Chief Financial OfficerAug 16Buy4.836,50031,39520,000Aug 16 04:24 PM
Chan Phillip P.President and CEOAug 15Option Exercise3.4575,000258,750641,188Aug 19 04:01 PM
Mortensen Eric R.Chief Medical OfficerAug 14Option Exercise4.505,00022,500148,932Aug 16 02:35 PM
BLOCH KATHLEEN P.Chief Financial OfficerAug 09Buy5.521,5008,27313,500Aug 13 06:08 PM
BLOCH KATHLEEN P.Chief Financial OfficerJun 07Option Exercise5.6010,00056,000252,725Jun 11 05:28 PM
Chan Phillip P.President and CEOJun 07Option Exercise4.3320,00086,500515,582Jun 11 04:59 PM
BLOCH KATHLEEN P.Chief Financial OfficerMay 10Buy6.493,00019,4763,000May 14 03:29 PM